Evidence Based Biomarker-Driven Advances in Ovarian & Endometrial Cancer: Equitable, Individualized and Accessible Care Industry Supported Symposium

This course offers a clinically relevant exploration of evolving treatment strategies in ovarian and endometrial cancers for a global audience.  The primary focus of this course will help learners understand how to make biomarker-driven decisions for on-label therapeutic pathways. Learners will deepen their understanding of the role of BRCA, HRD, MMR/MSI, and emerging biomarkers such as p53 for equitable and individualized care treatment plans that aim to improve patient outcomes.

Through cased-based learning, the program emphasizes the real-world application of molecular testing, including how to interpret biomarker results and integrate them into treatment.  Key trials such as SOLO-1, PAOLA-1, PRIMA, DUO-E and ARIEL3 will be discussed to illustrate evidence-based approaches to selecting the right therapy for the right patient, particularly in the context of PARP inhibitor use and HRD testing as well as target based ADCs.  The course acknowledges geographic disparities, particularly in areas with limited on-the-ground support and aims to provide practical guidance for clinicians who are working to implement testing and treatment strategies under local constraints.  Additionally, the program will explore emerging therapeutic targets and biomarkers, including the potential of antibody-drug conjugates (ADCs), Her2 and Folate Receptor Alpha, and discuss how evolving science is reshaping treatment landscapes. Consideration will be given to health equity, access to testing, and the implementation challenges faced by clinicians and patients across diverse care environments.

This educational activity is supported by an independent medical education grant from AstraZeneca.

Target Audience

Gynecologic and medical oncologists, oncology researchers, clinical trial investigators, advanced practice providers, and healthcare professionals involved in the care of patients with ovarian cancer.

Learning Objectives

Upon completion of the activities in this series, learners will be able to:

• Apply evidence-based treatment strategies for ovarian and endometrial cancers.
  
• • Focus on guideline-aligned approaches and biomarker-informed therapies
  • Reference key clinical trials (e.g., SOLO-1, PRIMA, PAOLA-1) where applicable
• Integrate biomarker testing into clinical decision-making
• • Understand the role of BRCA, HRD, MMR/MSI, and p53 in treatment selection
  • Interpret test results and apply them across disease types and clinical contexts
•  Identify practical challenges to biomarker testing and treatment access.
• • Explore disparities in testing availability and therapeutic access
  • Implement strategies to promote equitable care, particularly in resource-limited settings
• Recognize emerging therapeutic targets and evolving biomarkers.
• • Discuss ADCs, including HER2 and Folate Receptor Alpha, and other novel approaches within the context of approved and investigational options
  • Stay informed about evolving biomarker algorithms and their clinical implications